摘要
自身免疫性脑炎(autoimmune encephalitis, AE)是一种非感染性的自身免疫反应介导的炎性脑病。随着自身抗体相关疾病的研究进展,AE的治疗逐渐成为神经免疫领域的研究热点。AE的常规治疗为免疫治疗,大多数患者经一线及二线免疫治疗后症状好转,但仍有部分患者经免疫治疗后效果欠佳。托珠单抗(tocilizumab, TCZ)作为一种白介素-6受体拮抗剂,在难治性AE中的应用逐渐增多,本文对TCZ应用于难治性AE的国内外研究现状进行综述。
Autoimmune encephalitis(AE)is associated with immune-mediated antigen-antibody reactions involving the central nervous system.With the advent of autoantibody-associated diseases,the therapy of AE has become a hot research frontier in neuroimmunology.The conventional treatments of AE include first-line therapy and second-line therapy.The first-line treatments of AE include steroids,intravenous immunoglobulin(IVIG),plasma exchange(PLEX),and second-line therapy includes rituximab.However,current conventional therapy is ineffective for a considerable number of patients with AE.According to the current clinical trial evidence and single reports,tocilizumab is effective for refractory AE patients.With the current rapid research progress,a breakthrough in the treatment of AE is critical.This article aims to review tocilizumab in the treatment of refractory AE.
作者
张方圆
郭守刚
ZHANG Fangyuan;GUO Shougang(Qilu Medical College,Shandong University,Jinan 250012,China;Department of Neurology,Shandong Provincial Hospital Affiliated to Shandong First medical University,Jinan 250021,China)
出处
《山东第一医科大学（山东省医学科学院）学报》
CAS
2023年第5期396-400,共5页
Journal of Shandong First Medical University ＆ Shandong Academy of Medical Sciences
